BACKGROUND: Serology for human papillomaviruses (HPV) types -16 and -18 is established as an important tool for studies of HPV vaccinology and epidemiology. However, as there are a large number of oncogenic genital types of HPV there is a need for development of high-throughput, validated HPV serological assays that can be used for more comprehensive seroepidemiological studies and for research on multivalent HPV vaccines. OBJECTIVES: To develop a multiplexed pseudovirion-based serological assay (PsV-Luminex) encompassing 21 HPV types and validate the method by correlating the serology with the presence of type specific HPV DNA in cervical samples. STUDY DESIGN: Cervical swabs from 3,291 unvaccinated women attending organized cervical screening in Slovenia were tested with 3 different HPV DNA detection methods and presence of HPV DNA compared to presence of serum antibodies to pseudovirions from 15 genital HPV types (HPV-6,-11,-16,-18,-31,-33,-35,-39,-45,-52,-56,-58,-59,-68,-73). RESULTS: On average 51% of the HPV DNA positive women were seropositive for the same HPV type that was detected in the cervical specimen. We found a strong correlation with presence of HPV DNA and antibodies to the same HPV type for 13/15 genital HPV types (median OR = 5.7, CI 95% = 2.4-12.9). HPV-52 serology failed the validation and HPV-11 serology could not be validated because only a single woman was positive for HPV-11 DNA. The correlation between serology and HPV DNA status tended to be stronger among women infected with single HPV type (median OR=10.5, CI 95% = 2.4-48.4) than among women with multiple HPV infections (median OR = 4.6, CI 95% = 1.8-11.7). CONCLUSIONS: A multiplexed HPV PsV-Luminex assay has been developed and validated to correlate with natural HPV infection for 13 HPV types, thus enabling more comprehensive studies in HPV epidemiology and vaccine research.
BACKGROUND: Serology for human papillomaviruses (HPV) types -16 and -18 is established as an important tool for studies of HPV vaccinology and epidemiology. However, as there are a large number of oncogenic genital types of HPV there is a need for development of high-throughput, validated HPV serological assays that can be used for more comprehensive seroepidemiological studies and for research on multivalent HPV vaccines. OBJECTIVES: To develop a multiplexed pseudovirion-based serological assay (PsV-Luminex) encompassing 21 HPV types and validate the method by correlating the serology with the presence of type specific HPV DNA in cervical samples. STUDY DESIGN: Cervical swabs from 3,291 unvaccinated women attending organized cervical screening in Slovenia were tested with 3 different HPV DNA detection methods and presence of HPV DNA compared to presence of serum antibodies to pseudovirions from 15 genital HPV types (HPV-6,-11,-16,-18,-31,-33,-35,-39,-45,-52,-56,-58,-59,-68,-73). RESULTS: On average 51% of the HPV DNA positive women were seropositive for the same HPV type that was detected in the cervical specimen. We found a strong correlation with presence of HPV DNA and antibodies to the same HPV type for 13/15 genital HPV types (median OR = 5.7, CI 95% = 2.4-12.9). HPV-52 serology failed the validation and HPV-11 serology could not be validated because only a single woman was positive for HPV-11 DNA. The correlation between serology and HPV DNA status tended to be stronger among women infected with single HPV type (median OR=10.5, CI 95% = 2.4-48.4) than among women with multiple HPV infections (median OR = 4.6, CI 95% = 1.8-11.7). CONCLUSIONS: A multiplexed HPV PsV-Luminex assay has been developed and validated to correlate with natural HPV infection for 13 HPV types, thus enabling more comprehensive studies in HPV epidemiology and vaccine research.
Authors: David P Durham; Martial L Ndeffo-Mbah; Laura A Skrip; Forrest K Jones; Chris T Bauch; Alison P Galvani Journal: Proc Natl Acad Sci U S A Date: 2016-04-18 Impact factor: 11.205
Authors: Andrea Trevisan; João M G Candeias; Patrícia Thomann; Luisa L Villa; Eduardo L Franco; Helen Trottier Journal: J Med Microbiol Date: 2020-07 Impact factor: 2.472
Authors: Xavier Castellsagué; Paulo Naud; Song-Nan Chow; Cosette M Wheeler; Maria Julieta V Germar; Matti Lehtinen; Jorma Paavonen; Unnop Jaisamrarn; Suzanne M Garland; Jorge Salmerón; Dan Apter; Henry Kitchener; Julio C Teixeira; S Rachel Skinner; Genara Limson; Anne Szarewski; Barbara Romanowski; Fred Y Aoki; Tino F Schwarz; Willy A J Poppe; F Xavier Bosch; Newton S de Carvalho; Klaus Peters; Wiebren A A Tjalma; Mahboobeh Safaeian; Alice Raillard; Dominique Descamps; Frank Struyf; Gary Dubin; Dominique Rosillon; Laurence Baril Journal: J Infect Dis Date: 2014-03-08 Impact factor: 5.226
Authors: Dominique Rosillon; Laurence Baril; Maria Rowena Del Rosario-Raymundo; Cosette Marie Wheeler; Susan Rachel Skinner; Suzanne Marie Garland; Jorge Salmeron; Eduardo Lazcano-Ponce; Carlos Santiago Vallejos; Tanya Stoney; Bram Ter Harmsel; Timothy Yong Kuei Lim; Swee Chong Quek; Galina Minkina; Shelly Ann McNeil; Celine Bouchard; Kah Leng Fong; Deborah Money; Arunachalam Ilancheran; Alevtina Savicheva; Margaret Cruickshank; Archana Chatterjee; Alison Fiander; Mark Martens; Marie Cecile Bozonnat; Frank Struyf; Gary Dubin; Xavier Castellsagué Journal: Cancer Med Date: 2019-07-05 Impact factor: 4.452